Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: A groupwide Southwest Oncology Group study

Thomas P Miller, Steve Dahlberg, James K. Weick, Joseph C. Files, Harmon J. Eyre, Kelly B. Pendergrass, Richard I. Fisher

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Chemotherapy using cyclophosphamide, doxorubicin, etoposide, cytarabine, bleomycin, vincristine, methotrexate with leucovorin, and prednisone (ProMACE-CytaBOM) for patients with intermediate- and high-grade non-Hodgkin's lymphomas was tested by the Southwest Oncology Group (SWOG) to confirm the activity of the regimen and to test the feasibility and safety of administering third-generation drug regimens in a cooperative group setting. On day 1, cyclophosphamide, doxorubicin, and etoposide were administered, followed by eytarabine, bleomycin, vincristine and methotrexate with leucovorin given on day 8. There were 51 complete remissions (CRs) among 78 previously untreated patients (65%) having clinical stage II-IV disease. The median length of follow-up is 37.9 months with 57% of patients alive at 3 years and 50% of CR patients free of disease at 3 years. Patients with diffuse large-cell lymphoma have the best survival (63% at 3 years) and relapse-free survival (RFS; 68% at 3 years with no relapses seen after 14 months). Administration of ProMACE-CytaBOM is feasible and safe in a cooperative group setting with 84% of 537 courses of treatment given exactly according to schedule and fatal toxicities seen in five patients (6%). ProMACE-CytaBOM may represent improved treatment for diffuse large-cell lymphoma, but the modest differences compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) indicate the need for a prospective randomized comparative trial.

Original languageEnglish (US)
Pages (from-to)1951-1958
Number of pages8
JournalJournal of Clinical Oncology
Volume8
Issue number12
StatePublished - Dec 1990
Externally publishedYes

Fingerprint

Non-Hodgkin's Lymphoma
Histology
Vincristine
Doxorubicin
Cyclophosphamide
Leucovorin
Lymphoma, Large B-Cell, Diffuse
Bleomycin
Etoposide
Prednisone
Methotrexate
Recurrence
Survival
Cytarabine
Appointments and Schedules
Safety
Drug Therapy
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Miller, T. P., Dahlberg, S., Weick, J. K., Files, J. C., Eyre, H. J., Pendergrass, K. B., & Fisher, R. I. (1990). Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: A groupwide Southwest Oncology Group study. Journal of Clinical Oncology, 8(12), 1951-1958.

Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM : A groupwide Southwest Oncology Group study. / Miller, Thomas P; Dahlberg, Steve; Weick, James K.; Files, Joseph C.; Eyre, Harmon J.; Pendergrass, Kelly B.; Fisher, Richard I.

In: Journal of Clinical Oncology, Vol. 8, No. 12, 12.1990, p. 1951-1958.

Research output: Contribution to journalArticle

Miller, TP, Dahlberg, S, Weick, JK, Files, JC, Eyre, HJ, Pendergrass, KB & Fisher, RI 1990, 'Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: A groupwide Southwest Oncology Group study', Journal of Clinical Oncology, vol. 8, no. 12, pp. 1951-1958.
Miller, Thomas P ; Dahlberg, Steve ; Weick, James K. ; Files, Joseph C. ; Eyre, Harmon J. ; Pendergrass, Kelly B. ; Fisher, Richard I. / Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM : A groupwide Southwest Oncology Group study. In: Journal of Clinical Oncology. 1990 ; Vol. 8, No. 12. pp. 1951-1958.
@article{d4a76693bf71417a976fc09c12a017a1,
title = "Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: A groupwide Southwest Oncology Group study",
abstract = "Chemotherapy using cyclophosphamide, doxorubicin, etoposide, cytarabine, bleomycin, vincristine, methotrexate with leucovorin, and prednisone (ProMACE-CytaBOM) for patients with intermediate- and high-grade non-Hodgkin's lymphomas was tested by the Southwest Oncology Group (SWOG) to confirm the activity of the regimen and to test the feasibility and safety of administering third-generation drug regimens in a cooperative group setting. On day 1, cyclophosphamide, doxorubicin, and etoposide were administered, followed by eytarabine, bleomycin, vincristine and methotrexate with leucovorin given on day 8. There were 51 complete remissions (CRs) among 78 previously untreated patients (65{\%}) having clinical stage II-IV disease. The median length of follow-up is 37.9 months with 57{\%} of patients alive at 3 years and 50{\%} of CR patients free of disease at 3 years. Patients with diffuse large-cell lymphoma have the best survival (63{\%} at 3 years) and relapse-free survival (RFS; 68{\%} at 3 years with no relapses seen after 14 months). Administration of ProMACE-CytaBOM is feasible and safe in a cooperative group setting with 84{\%} of 537 courses of treatment given exactly according to schedule and fatal toxicities seen in five patients (6{\%}). ProMACE-CytaBOM may represent improved treatment for diffuse large-cell lymphoma, but the modest differences compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) indicate the need for a prospective randomized comparative trial.",
author = "Miller, {Thomas P} and Steve Dahlberg and Weick, {James K.} and Files, {Joseph C.} and Eyre, {Harmon J.} and Pendergrass, {Kelly B.} and Fisher, {Richard I.}",
year = "1990",
month = "12",
language = "English (US)",
volume = "8",
pages = "1951--1958",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "12",

}

TY - JOUR

T1 - Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM

T2 - A groupwide Southwest Oncology Group study

AU - Miller, Thomas P

AU - Dahlberg, Steve

AU - Weick, James K.

AU - Files, Joseph C.

AU - Eyre, Harmon J.

AU - Pendergrass, Kelly B.

AU - Fisher, Richard I.

PY - 1990/12

Y1 - 1990/12

N2 - Chemotherapy using cyclophosphamide, doxorubicin, etoposide, cytarabine, bleomycin, vincristine, methotrexate with leucovorin, and prednisone (ProMACE-CytaBOM) for patients with intermediate- and high-grade non-Hodgkin's lymphomas was tested by the Southwest Oncology Group (SWOG) to confirm the activity of the regimen and to test the feasibility and safety of administering third-generation drug regimens in a cooperative group setting. On day 1, cyclophosphamide, doxorubicin, and etoposide were administered, followed by eytarabine, bleomycin, vincristine and methotrexate with leucovorin given on day 8. There were 51 complete remissions (CRs) among 78 previously untreated patients (65%) having clinical stage II-IV disease. The median length of follow-up is 37.9 months with 57% of patients alive at 3 years and 50% of CR patients free of disease at 3 years. Patients with diffuse large-cell lymphoma have the best survival (63% at 3 years) and relapse-free survival (RFS; 68% at 3 years with no relapses seen after 14 months). Administration of ProMACE-CytaBOM is feasible and safe in a cooperative group setting with 84% of 537 courses of treatment given exactly according to schedule and fatal toxicities seen in five patients (6%). ProMACE-CytaBOM may represent improved treatment for diffuse large-cell lymphoma, but the modest differences compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) indicate the need for a prospective randomized comparative trial.

AB - Chemotherapy using cyclophosphamide, doxorubicin, etoposide, cytarabine, bleomycin, vincristine, methotrexate with leucovorin, and prednisone (ProMACE-CytaBOM) for patients with intermediate- and high-grade non-Hodgkin's lymphomas was tested by the Southwest Oncology Group (SWOG) to confirm the activity of the regimen and to test the feasibility and safety of administering third-generation drug regimens in a cooperative group setting. On day 1, cyclophosphamide, doxorubicin, and etoposide were administered, followed by eytarabine, bleomycin, vincristine and methotrexate with leucovorin given on day 8. There were 51 complete remissions (CRs) among 78 previously untreated patients (65%) having clinical stage II-IV disease. The median length of follow-up is 37.9 months with 57% of patients alive at 3 years and 50% of CR patients free of disease at 3 years. Patients with diffuse large-cell lymphoma have the best survival (63% at 3 years) and relapse-free survival (RFS; 68% at 3 years with no relapses seen after 14 months). Administration of ProMACE-CytaBOM is feasible and safe in a cooperative group setting with 84% of 537 courses of treatment given exactly according to schedule and fatal toxicities seen in five patients (6%). ProMACE-CytaBOM may represent improved treatment for diffuse large-cell lymphoma, but the modest differences compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) indicate the need for a prospective randomized comparative trial.

UR - http://www.scopus.com/inward/record.url?scp=0025646648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025646648&partnerID=8YFLogxK

M3 - Article

C2 - 1700079

AN - SCOPUS:0025646648

VL - 8

SP - 1951

EP - 1958

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 12

ER -